Skip to content
MARKETS / NASDAQ / LFVN
NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP

Lifevantage Corp. LFVN

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$182.6M
▼ 20.1% YoY
$5.1M
▼ 48.3% YoY
$6.7M
▼ 36.5% YoY
In brief

What this company does

LifeVantage Corporation engages in the identification, research, development, formulation and sale of nutrigenomic activators, dietary supplements, weight management products, pre- and pro-biotics, skin and hair care products, and nootropics. It provides its products to customers and independent consultants, along with a commission-based direct sales opportunity offered to its independent consultants. It sells its products in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, and Singapore. Its product lines include Protandim, a line of dietary supplements; LifeVantage, a line of dietary supplements that includes the MindBody GLP-1 System, Omega+, ProBio, IC Bright, the Rise AM & Reset PM System, D3+, and Daily Wellness; PhysIQ, its Fat Burn and Prebiotic dietary supplements; TrueScience, its line of skin and hair care products and Liquid Collagen; Petandim, its companion pet supplement formulated to combat oxidative stress in dogs; and AXIO, its nootropic energy drink mixes. It was incorporated in Colorado in June 1988 under the name Andraplex Corporation, changed its name to Yaak River Resources, Inc. in January 1992, and changed it again to Lifeline Therapeutics, Inc. in October 2004. In November 2006, it changed its name to LifeVantage Corporation. In 2018, it reincorporated from the State of Colorado to the State of Delaware.

Written from the business description in Lifevantage Corp's annual report to the U.S. Securities and Exchange Commission, filed 4 September 2025. Every sentence was checked against that document before publication.

Growth
USD 182.6M
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 182.6 · Net income 5.1
80M160M-20M-40M201020122014201620182020202220242025
Compound annual growth
−5.1%
−3.7%
−1.2%
+10.9%
+25.9%
−17.0%
−1.8%
+26.0%
−15.0%
−0.5%
+14.0%
+22.1%
−18.1%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −3.7% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
3 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 3.3% · Net 2.8%
5%10%15%-50%-100%201020122014201620182020202220242025
ROE
FY2025 · ROE 14.9%
100%200%300%201020122014201620182020202220242025

Each USD of equity produced 15 cents of profit this year.

Cash & shareholders
USD 4.4M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 6.7
8M16M201020122014201620182020202220242025
Net buybacks $M Dividends $M
FY2025 · Dividends 2.3 · Net buybacks 2.0
20M40MDividendsNet buybacks201020122014201620182020202220242025

USD 2.3M in dividends and USD 2.0M in buybacks — 86% of the year's profit went back to shareholders.

Total assetsUSD 62.1M
EquityUSD 33.6M
CashUSD 14.9M
Current ratio1.89×

Equity funds 54% of total assets.

The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B0.20.20.20.20.20.20.20.20.20.20.20.20.20.20.10.0
Operating income $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
EBITDA $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Income tax $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Net income $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0−0.1
Free cash flow $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
EPS, diluted $0.400.750.230.200.240.900.790.500.410.110.420.500.710.060.11−0.69
Dividend / sh $0.180.170.550.120.03···········
Payout %4621236621200·········
ROE %14.932.39.77.79.136.838.230.231.612.898.0344.362.824.5333.6·
Shares out B0.010.010.010.010.010.010.010.010.010.010.010.010.100.120.110.10

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures · 1 divergences in 80 reconciliationsAUDITED

Reconciled in 15 of 19 fiscal years. 1 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 15 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures1 divergent
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated innot stated in the filings
Fiscal year endsJune 30
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image